Lisata Therapeutics
LSTA
28 hedge funds and large institutions have $2.15M invested in Lisata Therapeutics in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 19 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
22% less capital invested
Capital invested by funds: $2.76M → $2.15M (-$612K)
35% less funds holding
Funds holding: 43 → 28 (-15)
79% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
+$5.97M |
| 2 |
HCM
Hollencrest Capital Management
Newport Beach,
California
|
+$660K |
| 3 |
Renaissance Technologies
New York
|
+$150K |
| 4 |
EGA
Eagle Global Advisors
Houston,
Texas
|
+$147K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$53.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$900K |
| 2 |
Bank of New York Mellon
New York
|
-$50K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$40K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$39K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$36.4K |
LSTA Hedge Fund Activity: Q3 2016 in Review
28 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q3 2016, worth a combined $2.15M — down 22% from $2.76M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of LSTA and 4 opened new positions — a net loss of 15 holders — while 5 trimmed existing stakes and 7 added.
The largest buyer was Pine River Capital Management, adding an estimated $5.97M. The largest seller was Great Point Partners, exiting entirely with an estimated $900K sold.
- 28 institutional investors held Lisata Therapeutics (LSTA) as of Q3 2016, down from 43 in Q2 2016.
- Funds reported $2.15M of Lisata Therapeutics stock for Q3 2016, down 22% quarter-over-quarter.
- 4 funds opened new Lisata Therapeutics positions in Q3 2016 and 19 closed out, a net change of -15 holders.
- The largest Lisata Therapeutics buyer in Q3 2016 was Pine River Capital Management, an estimated $5.97M added.
- The largest Lisata Therapeutics seller in Q3 2016 was Great Point Partners, an estimated $900K sold.
Based on aggregated 13F filings for Q3 2016.